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Abstract
Objectives: To assess outcomes in patients with acute mitral regurgitation
(MR) following acute myocardial infarction (AMI) who received percutaneous mitral
valve repair (PMVR) with the MitraClip device and to compare outcomes of patients
who developed cardiogenic shock (CS) to those who did not (non-CS).
Background: Acute MR after AMI may lead to CS and is associated with high
mortality.
Methods: This registry analyzed patients with MR after AMI who were treated
with MitraClip at 18 centers within eight countries between January 2016 and
February 2020. Patients were stratified into CS and non-CS groups. Primary outcomes were mortality and rehospitalization due to heart failure. Secondary outcomes were acute procedural success, functional improvement, and MR reduction.
Multivariable Cox regression analysis evaluated association of CS with clinical
outcomes.
Results: Among 93 patients analyzed (age 70.3 ± 10.2 years), 50 patients (53.8%)
experienced CS before PMVR. Mortality at 30 days (10% CS vs. 2.3% non-CS;
p = .212) did not differ between groups. After median follow-up of 7 months (IQR
2.5–17 months), the combined event mortality/re-hospitalization was similar (28%
CS vs. 25.6% non-CS; p = .793). Likewise, immediate procedural success (90% CS
vs. 93% non-CS; p = .793) and need for reintervention (CS 6% vs. non-CS 2.3%,
p = .621) or re-admission due to HF (CS 13% vs. NCS 23%, p = .253) at 3 months
did not differ. CS was not independently associated with the combined end-point
(hazard ratio 1.1; 95% CI, 0.3–4.6; p = .889).
Conclusions: Patients found to have significant MR during their index hospitalization for AMI had similar clinical outcomes with PMVR whether they presented in or
out of cardiogenic shock, provided initial hemodynamic stabilization was first
achieved before PMVR.
KEYWORDS

acute myocardial infarction, cardiogenic shock, MitraClip, mitral regurgitation, percutaneous
mitral valve repair
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I N T RO DU CT I O N

degree of MR,4 in some cases, MR remains unaltered or worsens,
potentially leading to clinical deterioration that may prompt

Acute mitral regurgitation (MR) may develop in the setting of an

intervention.

acute myocardial infarction (AMI) as a result of papillary muscle dys-

Until recently, the only intervention for correcting MR was sur-

function or rupture. Acute MR is a severe complication that may

gery; however, surgery is associated with high rates of morbidity and

occur in up to 3% of AMI patients, is more prevalent in patients pre-

increased mortality nearing 20–25%.6 Additionally, patients treated

senting with hemodynamic instability, and has been linked to a

solely with medical therapy have the highest mortality rates.7 There-

worse prognosis even in the modern era of transcatheter reperfu-

fore, the development of less invasive interventions for repairing MR

sion.

1-4

Acute MR without papillary muscular rupture may induce

would be beneficial. The method of percutaneous mitral valve repair

severe MR due to leaflet tethering produced by the sudden onset of

(PMVR) with the MitraClip device (Abbot Vascular, Santa Clara,

regional or global left ventricular dysfunction and can lead to pulmo-

California) has been shown to be a safe and effective technique for

nary edema or cardiogenic shock (CS) during the acute or subacute

reducing MR in patients who are at high risk for open-heart surgery,8

5

phase of the MI. Thus, more commonly patients who present with

and this method can improve symptoms, quality of life, and prognosis

AMI may also be found to have severe functional mitral regurgita-

in patients with functional MR.9-12 Whereas most MR cases are in

tion. Although percutaneous revascularization may improve the

patients who are in a stable clinical situation with advanced functional

3
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class and chronic MR, patients with acute MR are underrepresented

transesophageal echocardiogram and fluoroscopic guidance. Prep-

in registries and randomized trials.

rocedural transthoracic and transesophageal echocardiography were

Although experiences with MitraClip for correcting MR following
AMI have been reported,13-17 data on the effect of this treatment in

performed in all patients for semiquantitative MR analysis and to
assess morphologic suitability for MitraClip implantation.

patients who develop CS during the event are lacking, and the issue
remains understudied. The aim of this registry-based study was to
assess procedural, clinical, and echocardiographic outcomes of

3.4
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Study end points

patients with acute MR after AMI who were treated by PMVR with
the MitraClip device and to assess whether patients who developed

Baseline and echocardiographic features and immediate procedural out-

CS had different outcomes from those who did not (non-CS).

comes were collected. Procedural and clinical adverse events during
follow-up were defined according to the Mitral Valve Academic
Research Consortium.22 Technical success was defined as correct

2

METHODS

|

implantation of at least one clip and the absence of procedural mortality
or emergent cardiovascular intervention related to the device or the

We performed a registry-based record review study by assessing all

access site. Immediate procedural success was defined as technical suc-

consecutive patients who were found to have severe MR when pre-

cess associated with a reduction of MR to ≤2+. Procedural success at

senting with AMI and who underwent PMVR with the MitraClip

30-days follow-up was defined as device success in the absence of life-

device in 18 centers worldwide between January 2016 and January

threatening bleeding, major vascular or structural complications, MI,

2020. A list of participating centers is shown in Table S1.

severe acute kidney injury, or hemodynamic instability. Total mortality
and admission due to heart failure were the main clinical end-points.
Secondary outcomes were acute procedural success, periprocedural

3
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complications, functional improvement, and MR reduction.
Echocardiographic and clinical follow-up were carried out per

3.1

|

Inclusion criteria

New York Heart Association functional classification. Patients were
contacted by phone if necessary. Data collection was approved by the

Patients were included in the study who had an AMI in the prior

local ethics committee of every institution and written informed con-

4 weeks and experienced symptomatic severe MR that was diag-

sent was obtained.

nosed by transthoracic echocardiogram or transesophageal echocardiogram following current guidelines and recommendations.18,19
Symptoms of MR were different from heart failure to CS. All patients

3.5
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Statistical analysis

were considered by a heart team to be at high risk for conventional
surgery.

Continuous variables were summarized as mean ± SD or as median
and interquartile range (IQR). Comparisons were made using unpaired
Student's t-test or the nonparametric Wilcoxon rank sum test if data

3.2
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Exclusion criteria

did not follow a normal distribution. Distribution normality was
assessed with the Shapiro–Wilk test. Categorical variables were

Patients were excluded if their anatomy was not suitable for MitraClip

described as percentages and were compared using Chi-square test

implantation.

for frequencies greater than 5 and Fisher exact test for frequencies

All patients were cared for following current practice guidelines

less than 5. Survival curves for time-to-event were constructed using

for both AMI and acute heart failure.6,20 Administration of intrave-

all available follow-up data with Kaplan–Meier estimates. Compari-

nous diuretics and inotropes/vasopressors and indication for mechani-

sons between CS and non-CS patients were performed using the log-

cal ventilation or circulatory support before PMVR were conducted

rank test. A Cox-regression analysis adjusted by age, EuroScore II, and

based on attending team criteria. Patients with CS included those

acute procedural success was performed to evaluate the independent

patients who fulfilled the CS definition of the Society for Cardiovascu-

effect of CS on clinical events. A p-value <.05 was considered statisti-

lar Angiography and Intervention Stage C-E.21 The timing of shock

cally significant. Statistical analyses were performed using SPSS ver-

evaluation to classify patients was the time of MitraClip strategy

sion 25.0. (IBM Corp. Released 2017. IBM SPSS Statistics for

decision.

Windows, Version 25.0. Armonk, NY: IBM Corp.).

3.3
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Procedure
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RE SU LT S

All procedures were performed in a cardiac catheterization laboratory

A total of 93 records in the IREMMI registry of patients who had

or in a hybrid room, and patients were under general anesthesia using

mitral valve repair with the MitraClip device between January 2016

4
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Total n = 93

CS n = 50

Non-CS n = 43

p-value

Age, years

70 ± 10

68 ± 10

72 ± 9

.061

Male, n (%)

45 (48)

25 (50)

20 (46)

.836

Diabetes, n (%)

40 (43)

23 (46)

17 (40)

.672

Hypertension, n (%)

65 (70)

33 (66)

32 (74)

.486

BMI (kg/m2)

26 ± 5

26 ± 4

26 ± 5

.574

TABLE 1

Baseline characteristics

Variables

Dyslipidaemia, n (%)

58 (62)

28 (56)

30 (69)

.192

COPD, n (%)

16 (17)

7 (14)

9 (21)

.417

Previous MI, n (%)

53 (57)

28 (56)

25 (58)

1.000

Previous stroke, n (%)

13 (14)

9(18)

4 (9)

.368

Previous CABG, n (%)

25 (27)

14 (28)

11 (25)

.817

Previous CKD, n (%)

45 (48)

20 (40)

25 (58)

.081

Euroscore 2, mean ± SD

16 ± 15

21 ± 18

11 ± 8

.001

Infarct location

.013

Anterior

32 (35)

23 (46)

9 (21)

Inferior

44 (47)

16 (32)

28 (65)

Lateral

15 (16)

10 (20)

5 (12)

Undetermined

2 (2)

1 (2)

1 (2)

STEMI, n (%)

68 (73.1)

39 (78)

29 (67.4)

.502

Multivessel disease, n (%)

73 (78)

38 (76)

36 (83)

.404

Primary PCI, n (%)

66 (71)

38 (76)

28 (65)

.159

IABP/Impella

36 (38)

33 (66)

3 (7)

<.001

VA ECMO

6 (6)

6 (12)

0 (0)

.028

Vasoactive drugs

43 (46)

41 (82)

2 (4)

<.001

LVEF (%)

36 ± 12

34 ± 12

38 ± 11

.079

MCS

MR grade 4+, n (%)

77 (83)

43 (86)

34 (79)

.377

Systolic PAP (mmHg)

54 ± 19

53 ± 21

55 ± 18

.793

Abbreviations: BMI, body mass index; CABG, coronary artery by-pass graft; CKD, chronic kidney disease;
COPD, Chronic obstructive pulmonary disease; CS, cardiogenic shock; IABP, intraaortic balloon pump;
LVEF, left ventricle ejection fraction; MCS, mechanical cardiac support; MI, myocardial infarction; MR,
mitral regurgitation; NCS, non-cardiogenic shock; PCI, percutaneous coronary intervention; PAP,
pulmonary artery pressure; STEMI, ST-segment elevation myocardial infarction; VA ECMO, veno-arterial
extracorporeal membrane oxygenation.

and February 2020 were included in the study. The mean ± SD patient

46% vs. non-CS, 21%; p = .013). The percentage of primary percuta-

age was 70.3 ± 10.2 years and included 48 (51.6%) women and

neous coronary intervention was equivalent. Complete revasculariza-

45 (48.4%) men. Characteristics of the population are in Table 1.

tion was achieved in 86% of patients with multivessel disease, with no

Patients were divided into CS and non-CS groups. Of the 93 patients,

difference between CS and non-CS patients (p = .562). CS patients

50 (53.8%) were in CS prior to MitraClip procedure. SCAI categories

were prescribed vasoactive drugs more frequently (82 vs. 4%,

of cardiogenic shock were A 24.7%, B 21.5%, C 36.6%, D 15.1%, and

p < .001) and were more likely to have IABP/Impella pumps (66 vs.

D 2.1%. Compared with non-CS patients, patients with CS were youn-

7%, p < .001) or venoarterial extra-corporeal membrane oxygenation

ger (68 ± 10 vs. 72 ± 9 years; p = .061), had a lower prevalence of

(12 vs. 0%, p = .028). Of the patients with IABP, 3 non-CS patients

chronic kidney disease (40 vs. 58%; p = .081), had higher surgical risk

received prophylactic IABP implantation after diagnosis with severe

(21 ± 18% vs. 11 ± 8% Euroscore II; p = .001), and had shorter time

MR. Preprocedural MR was 4+ in 86% of CS patients and 79% in non-

elapsed between MI and MitraClip placement (24 ± 22 vs. 33

CS patients (p = .377). Left ventricular ejection fraction was lower in

± 23 days; p = .069) (Table 1). The prevalence of multi-vessel disease

CS patients, but no differences were observed regarding systolic pul-

was high (CS, 76% vs. non-CS, 83%; p = .404) and similar between

monary arterial pressure (SPAP). Six patients were reported to have

groups and anterior wall MI was more frequent in the CS group (CS,

partial or complete papillary muscle rupture.

5
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F I G U R E 1 New York Heart Association functional class at
3 months [Color figure can be viewed at wileyonlinelibrary.com]

4.1
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Procedural characteristics

Technical success was achieved in 100% of patients. MitraClip NT and
NTR devices were used in 80 patients, XTR devices were used in
10 patients, and a combination of clips was used in 3 patients. More

F I G U R E 2 MR reduction postprocedural (panel a) and at
3 months (panel b) [Color figure can be viewed at
wileyonlinelibrary.com]

than 1 clip was used in 58.1% of patients. Immediate procedural success was high, with no difference between groups (CS, 90% vs. non-CS,
After a median follow-up of 7 months (range 0–81 months, IQR

93%, p = .793). However, mean procedure length was longer in patients
with CS than in non-CS patients (143 ± 113 vs. 82 ± 44 min; p = .003).

2.7–17), overall mortality did not differ between groups (CS, 16% vs.

The percentage of in-hospital major complications (including partial

NCS, 9.3%; p = .377), and the combined event mortality/

clip detachment, air embolism, MI, stroke, vascular injury, pericardial

rehospitalization due to heart failure was similar (CS, 28% vs. NCS,

effusion, and bleeding events) was low after procedure and did not dif-

26%; p = .793). Survival curves for both end-points are shown in

fer between groups (CS, 4% vs. non-CS, 7%, p = .659). Overall, mean

Figure 3.

SPAP was significantly decreased after the procedure (before, 54

In a Cox-regression analysis adjusted by age, Euroscore II, and

± 19 mmHg vs. after, 44 ± 20 mmHg; p < .001), with no difference

procedural success, CS was not independently associated with the

between groups. The mean mitral valve gradient increased significantly

combined end-point (hazard ratio [HR], 1.1; 95% CI, 0.3–4.6;

after procedure (before, 1.7 ± 0.9 mmHg vs. after, 3.3 ± 1.6 mmHg;

p = .889). The only variable independently associated with the com-

p < .001). After PMVR, the gradient did not differ between CS and non-

bined end-point was the immediate procedural success (HR, 0.1; 95%

CS patients (CS, 3.7 ± 1.9 mmHg vs. non-CS, 3.6 ± 1.7 mmHg; p = .741).

CI, 0.01–0.6; p = .012). Univariate and multivariate analyses are
shown in Table 2.

4.2
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Clinical follow-up
5
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DI SCU SSION

At 30-day follow-up, mortality was higher in the CS group (10 vs.
2.3%), but the difference was not significant (p = .207). Procedural

To our knowledge, this is the largest registry-based study evaluating

success at 30 days was lower in patients with CS, but the difference

the outcomes of patients who developed acute MR after AMI and

was not significant (CS, 59% vs. non-CS, 74%; p = .136).

who received PMVR with the MitraClip device. Our data suggest that

At 3-month follow-up, there were no differences in the percent-

this procedure may be a safe and effective strategy for reducing MR

age of re-admissions due to heart failure (CS, 13% vs. non-CS, 23%,

and improving prognosis in such high-risk populations. Also, we

p = .253) or repeated MitraClip intervention or surgery (CS, 6%

observed no differences in outcomes after PMVR in patients with CS,

vs. non-CS, 2.3%; p = .621). New York Heart Association functional

suggesting that CS may not be an important factor for precluding

classifications improved significantly compared with baseline, but no

implementation of the therapy, providing that clinical stabilization

differences were observed between groups (Figure 1). Likewise, echo-

could be achieved to receive PMVR.

cardiographic evaluation during this period showed a marked reduc-

MR after AMI is a serious complication that occurs in roughly 3%

tion in MR with no difference between groups (Figure 2). Reduction in

of cases. Complete papillary muscle rupture is uncommon (0.25% of

SPAP persisted, and no differences were observed between groups

MIs in the percutaneous coronary intervention era) and is often fatal.23

(CS, 40 ± 13 mmHg vs. non-CS, 44 ± 19 mmHg; p = .441).

However, acute MR due to leaflet tethering, partial papillary muscle

6
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F I G U R E 3 Kaplan–Meier survival curves comparing CS and non-CS groups. Panel a: Survival free from death. Panel b: Survival free from
death and rehospitalization due to heart failure [Color figure can be viewed at wileyonlinelibrary.com]

Univariate

Multivariate

HR

95% CI

p

HR

95% CI

p

Age

0.99

0.95–1.03

.651

1.05

0.97–1.13

.227

CKD

1.11

0.48–2.60

.810

DM

1.90

0.81–4.46

.140

EuroScore II

1.02

0.99–1.05

.087

1.02

0.99–1.06

.154

Pre IHD

0.98

0.38–2.56

.979

LVEF

0.99

0.95–1.03

.592

Cardiogenic shock

0.97

0.42–2.24

.936

1.1

0.3–4.6

.889

Procedural success

0.18

0.06–0.57

.004

0.10

0.02–0.60

.012

MCS

0.60

0.23–1.54

.288

T A B L E 2 Univariate and multivariate
predictors of combined death/
rehospitalization due to heart failure
during follow-up

Abbreviations: CI, confidence interval; CKD, chronic kidney disease; DM, Diabetes Mellitus; HR, hazard
ratio; IHD, ischemic heart disease; LVEF, left ventricular ejection fraction; MCS, mechanical cardiac
support.

rupture, or new onset of left ventricular dysfunction may be more fre-

Until recently, cardiac surgery was the only option available for

quent, with a possible prevalence of 35%, according to a study of a

the treatment of MR, and a systematic review revealed a pooled

series of MI treated by primary percutaneous coronary intervention.4 In

30-day mortality rate of 19%, with some studies showing mortality

a cohort of surgical patients, complete papillary muscle rupture after

rates as high as 39%.7 Notwithstanding, in recent years PMVR has

MI-related MR was responsible for 45% of cases,24 which means that

been extensively developed, and MitraClip is the device that has been

severe functional MR after MI is common and may cause deterioration

used for PMVR most extensively so far.

in a patient's condition enough to justify intervention.

MitraClip has been shown to be safer than conventional surgery,

Regarding treatment of MR (excluding complete papillary muscle

although less effective.26 In real-world registries of patients with

rupture), it has been reported that revascularization by means of pri-

both degenerative and functional MR and who are at high-risk for

mary percutaneous coronary intervention can significantly improve

surgery, MitraClip use is associated with clinical improvements and a

the degree of MR and therefore should be a first line treatment.4 In

significant reduction of MR.10,11,27 However, most MitraClip inter-

our study, primary percutaneous coronary intervention was carried

ventions performed to date have been in patients who were in a sta-

out in almost 72% of cases. However, even after successful percuta-

ble clinical situation with advanced functional class and chronic (not

neous revascularization, the degree of MR may worsen, and further

acute) MR. Our data suggest that MitraClip could be a safe and

treatment may be required. When CS develops within the context of

effective alternative to surgical intervention in clinically unstable

MR, mortality rises significantly, and stabilization through pharmaco-

patients who have a high risk of 30-day mortality, and this therapy

logical afterload reduction and/or mechanical circulatory support may

may even be safe for the 10% of patients who develop CS, which is

be lifesaving. However, the use of this advanced support should not

encouraging.

be a destination therapy, but rather a bridge to a subsequent interventional therapy focused in correcting MR.1,6,25

In our study, we saw that clinical results of PMVR did not differ
significantly between CS and non-CS patients, despite the poorer

7
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clinical situation and lower left ventricular ejection fraction in patients

research and randomized trials are required to increase our knowledge

with CS. This underscores the fact that in a CS scenario, the main

in this setting.

component responsible for clinical deterioration is the MR and its deleterious hemodynamic effects rather than the role of pump failure.
This could explain the difference in mortality observed in our series

6
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compared with classic series of CS following MI28 or in those series of
PMVR in cardiogenic shock patients where patients were in a clinical

Our study had several limitations. First, is an observational study and the

unstable condition but after mainly a long-standing ischemic or non-

sample size was small and so should be interpreted with caution. We did

ischemic cardiomyopathy in an end-stage situation.29-31 On the other

not find a significant difference in mortality between CS and non-CS

hand, the time from MI to MR treatment was several weeks in our

patients, which could be related to a lack of statistical power. A larger

patient sample, and this could be related to the intention to stabilize

study with longer follow-up will be needed to clarify the effect of

the clinical condition with the belief medical therapy was the only

MitraClip in this scenario. Furthermore, we cannot exclude the presence

option for the MR, since patients were not surgical candidates and the

of a selection bias in CS patients, in the sense that only those who

MitraClip approach was rather new in this setting. However, treating

responded to the medical therapy and cardiac support were those who

the MR quickly produces such positive clinical benefits that the inter-

received PMVR. Time form MI to PMVR was long and that means that

vention should not be delayed. Thus, we advocate for early MR cor-

even CS patients responded to the medical therapy in some way. This

rection irrespective of lower left ventricular ejection fraction and

population can represent a better prognostic category and therefore our

development of CS.

conclusions may not be applicable to all patients in CS with significant

There are several potential advantages of using PMVR with

MR. Likewise, because of the small sample size and number of events,

MitraClip. First, this treatment can lead to a rapid decrease in left

the multivariable analysis was limited. Thus, results should be considered

ventricular, left atrium, and pulmonary artery pressures and an

hypothesis generating and not generalizable. Also, echocardiographic

increase of cardiac output after a successful correction of the MR,32

follow-up is lacking, so the effect on left ventricular remodeling has not

which may lead to a fast recovery. Second, the technique reduces

been evaluated. However, our aim was to assess correlation within the

risk of left ventricle damage induced by the systemic inflammatory

clinical setting, not to show possible positive effects on left ventricular

response, free radical injury, and myocardial oxidative stress associ-

parameters. Likewise, number of patients with subvalvular apparatus

ated with cardiopulmonary bypass.33 Moreover, MitraClip may also

rupture was small to draw definitive conclusions. Although if a successful

avoid the restraint of the mitral annular motion caused by mitral

repair can be achieved results seemed similar, larger series with these

rings or prosthesis and the development of abnormal septal motion

anatomies must be collected to assess the specific performance of

that may negatively impact left ventricle performance. In addition,

MitraClip in this population. The shock status is a dynamic variable and

acute MR often develops in a previously normal mitral valve, which

we defined it at the time of MitraClip strategy decision. What we cannot

usually translates into optimal leaflet tissue and coaptation for

ascertain is what was the SCAI classification at the beginning of the clini-

device therapy. Furthermore, the use of MitraClip does not preclude

cal course. Likewise, all patients were treated with MitraClip as a salvage

a delayed cardiac surgery in case the device fails. Finally, a relevant

strategy, but we cannot distinguish from the present study whether the

number of unstable patients are on double or triple antithrombotic

patients were stable enough or with recurrent deterioration despite

therapy after MI, and MitraClip may help prevent significant bleed-

MCS support. Lastly, procedures were performed in centers that had

ing complications that are common after open-heart surgery and

high levels of experience with PMVR using MitraClip. Thus, our findings

that may negatively impact the prognosis of unstable patients. How-

cannot be generalized to less experienced teams.

ever, challenges when implementing this therapy exist. Treating
acute MR is one of the most technically challenging MitraClip procedures. Lesion complexity, a small atrium that makes performing a

7

CONC LU SION

|

high puncture difficult, the clinical situation of the patient, and the
risk of impingement in papillary muscle make these cases very

Patients found to have significant MR during their index hospitaliza-

demanding. The fact that the only independent factor associated

tion for AMI had similar clinical outcomes with PMVR whether they

with clinical outcomes was immediate technical success underscores

presented in or out of cardiogenic shock, provided initial hemody-

the relevance of the high level of experience required for the

namic stabilization was first achieved before PMVR.

implanting team.
Interestingly, a recent review of shock management after MI25
only considers mitral valve surgery for acute MR after MI. Our data

7.1

Clinical perspective

|

suggest that, given the favorable safety/efficacy profile, PMVR should
at least be considered in patients with this condition if the attending

7.1.1

|

What is next?

team has enough experience. This strategy may be of special interest
in patients with CS, which represent complex cases where effective

Further research is warranted to confirm these results and to compare

and fast recovery with a low rate of complications is desirable. Further

the percutaneous approach with conventional surgery.
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What is new?

|

PMVR with the MitraClip device may be a promising therapeutic
strategy for patients with acute MR after AMI, with or without
CS. This may represent a valid alternative for such patients.

7.1.3

What is known?

|

Acute MR may develop following AMI, a condition associated with
development of CS and high mortality. Until recently, conventional
surgery was the only alternative, which is associated with significant
mortality.
CONF LICT OF IN TE RE ST
Rodrigo Estévez-Loureiro is consultant for Abbott Vascular and Boston Scientific. Dr. Taramasso is a consultant for Abbott Vascular, Boston Scientific, 4TECH, and CoreMedic; and has received speaker
honoraria from Edwards Lifesciences. Dr. Denti has served as a consultant for Abbott Vascular, 4Tech, Neovasc, and InnovHeart; and has
received honoraria from Abbott. Dabit Arzamendi is consultant for
Abbott Vascular. Dr. Xavier Freixa is consultants for Abbott Vascular.
Dr. Fam, has received speaker honoraria and travel or grant support
from Edwards Lifesciences Francesco Maisano received Grant and/or
Research Support from Abbott, Medtronic, Edwards Lifesciences,
Biotronik, Boston Scientific Corporation, NVT, Terumo; receives Consulting fees, Honoraria from Abbott, Medtronic, Edwards Lifesciences,
Swissvortex, Perifect, Xeltis, Transseptal solutions, Cardiovalve,
Magenta; has Royalty Income/IP Rights Edwards Lifesciencesand is
Shareholder of Cardiovalve, Cardiogard, Magenta, SwissVortex, Transseptalsolutions, 4Tech, Perifect. All other authors have reported that
they have no relationships relevant to the contents of this article to
disclose.
DATA AVAI LAB ILITY S TATEMENT
The data that support the findings of this study are available from the
corresponding author upon reasonable request.
ORCID
Rodrigo Estévez-Loureiro
Maurizio Taramasso
Marianna Adamo
Xavier Freixa
Neil Fam

https://orcid.org/0000-0001-5841-5514

https://orcid.org/0000-0001-7295-1153
https://orcid.org/0000-0002-3855-1815

https://orcid.org/0000-0002-3203-9060

https://orcid.org/0000-0002-1269-6733

Andrew Czarnecki
Isaac Pascual

https://orcid.org/0000-0002-3000-9722

https://orcid.org/0000-0001-5433-1364

Estefanía Fernández-Peregrina

https://orcid.org/0000-0002-3025-

8251
Mattia Di Pasquale
Ander Regueiro

https://orcid.org/0000-0002-4499-7725

https://orcid.org/0000-0001-5201-447X

RE FE R ENC E S
1. Watanabe N. Acute mitral regurgitation. Heart. 2019;105:671-677.

2. Lopez-Perez M, Estevez-Loureiro R, Lopez-Sainz A, et al. Long-term
prognostic value of mitral regurgitation in patients with ST-segment
elevation myocardial infarction treated by primary percutaneous coronary intervention. Am J Cardiol. 2014;113:907-912.
3. Mentias A, Raza MQ, Barakat AF, et al. Prognostic significance of
ischemic mitral regurgitation on outcomes in acute ST-elevation myocardial infarction managed by primary percutaneous coronary intervention. Am J Cardiol. 2017;119:20-26.
4. Nishino S, Watanabe N, Kimura T, et al. The course of ischemic mitral
regurgitation in acute myocardial infarction after primary percutaneous coronary intervention: from emergency room to long-term
follow-up. Circ Cardiovasc Imaging. 2016;9:e004841.
5. Sannino A, Grayburn PA. Ischemic mitral regurgitation after acute
myocardial infarction in the percutaneous coronary intervention era.
Circ Cardiovasc Imaging. 2016;9:e005323.
6. Ibanez B, James S, Agewall S, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with STsegment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of
the European Society of Cardiology (ESC). Eur Heart J. 2018;39:
119-177.
7. Alajaji WA, Akl EA, Farha A, Jaber WA, AlJaroudi WA. Surgical versus
medical management of patients with acute ischemic mitral regurgitation: a systematic review. BMC Res Notes. 2015;8:712.
8. Feldman T, Kar S, Elmariah S, et al. Randomized comparison of percutaneous repair and surgery for mitral regurgitation: 5-year results of
EVEREST II. J Am Coll Cardiol. 2015;66:2844-2854.
9. Maisano F, Franzen O, Baldus S, et al. Percutaneous mitral valve interventions in the real world: early and 1-year results from the ACCESSEU, a prospective, multicenter, nonrandomized post-approval study of
the MitraClip therapy in Europe. J Am Coll Cardiol. 2013;62:1052-1061.
10. Nickenig G, Estevez-Loureiro R, Franzen O, et al. Percutaneous mitral
valve edge-to-edge repair: in-hospital results and 1-year follow-up of
628 patients of the 2011-2012 pilot European sentinel registry. J Am
Coll Cardiol. 2014;64:875-884.
11. Puls M, Lubos E, Boekstegers P, et al. One-year outcomes and predictors of mortality after MitraClip therapy in contemporary clinical
practice: results from the German transcatheter mitral valve interventions registry. Eur Heart J. 2016;37:703-712.
12. Stone GW, Lindenfeld J, Abraham WT, et al. Transcatheter mitralvalve repair in patients with heart failure. N Engl J Med. 2018;379:
2307-2318.
13. Bilge M, Alemdar R, Yasar AS. Successful percutaneous mitral valve
repair with the MitraClip system of acute mitral regurgitation due to
papillary muscle rupture as complication of acute myocardial infarction. Catheter Cardiovasc Interv. 2014;83:E137-E140.
14. Estevez-Loureiro R, Arzamendi D, Freixa X, et al. Percutaneous mitral
valve repair for acute mitral regurgitation after an acute myocardial
infarction. J Am Coll Cardiol. 2015;66:91-92.
15. Adamo M, Curello S, Chiari E, et al. Percutaneous edge-to-edge mitral
valve repair for the treatment of acute mitral regurgitation complicating myocardial infarction: a single centre experience. Int J Cardiol.
2017;234:53-57.
16. Estevez-Loureiro R, Adamo M, Arzamendi D, et al. Transcatheter
mitral valve repair in patients with acute myocardial infarction:
insights from the European Registry of MitraClip in acute mitral
regurgitation following an acute myocardial infarction (EREMMI).
EuroIntervention. 2020;15:1248-1250.
17. Haberman D, Taramasso M, Czarnecki A, et al. Salvage MitraClip in
severe secondary mitral regurgitation complicating acute myocardial
infarction: data from a multicentre international study. Eur J Heart
Fail. 2019;21:1161-1164.
18. Baumgartner H, Falk V, Bax JJ, et al. ESC/EACTS guidelines for the
management of valvular heart disease. Eur Heart J. 2017;38:27392791.

9

ESTÉVEZ-LOUREIRO ET AL.

19. Nishimura RA, Otto CM, Bonow RO, et al. AHA/ACC focused update
of the 2014 AHA/ACC guideline for the management of patients with
valvular heart disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice
guidelines. Circulation. 2017;135:e1159-e1195.
20. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the
diagnosis and treatment of acute and chronic heart failure: the task
force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)developed with the
special contribution of the heart failure association (HFA) of the ESC.
Eur Heart J. 2016;37:2129-2200.
21. Baran DA, Grines CL, Bailey S, et al. SCAI clinical expert consensus
statement on the classification of cardiogenic shock: this document
was endorsed by the American College of Cardiology (ACC), the
American Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the Society of Thoracic Surgeons (STS) in April
2019. Catheter Cardiovasc Interv. 2019;94:29-37.
22. Stone GW, Adams DH, Abraham WT, et al. Clinical trial design principles and endpoint definitions for Transcatheter mitral valve repair
and replacement: part 2: endpoint definitions: a consensus document
from the mitral valve academic research consortium. J Am Coll Cardiol. 2015;66:308-321.
23. French JK, Hellkamp AS, Armstrong PW, et al. Mechanical complications after percutaneous coronary intervention in ST-elevation myocardial infarction (from APEX-AMI). Am J Cardiol. 2010;105:59-63.
24. Chevalier P, Burri H, Fahrat F, et al. Perioperative outcome and longterm survival of surgery for acute post-infarction mitral regurgitation.
Eur J Cardiothorac Surg. 2004;26:330-335.
25. Thiele H, Ohman EM, de Waha-Thiele S, Zeymer U, Desch S. Management of cardiogenic shock complicating myocardial infarction: an
update 2019. Eur Heart J. 2019;40:2671-2683.
26. Feldman T, Foster E, Glower DD, et al. Percutaneous repair or surgery
for mitral regurgitation. N Engl J Med. 2011;364:1395-1406.
27. Sorajja P, Mack M, Vemulapalli S, et al. Initial experience with commercial transcatheter mitral valve repair in the United States. J Am
Coll Cardiol. 2016;67:1129-1140.

28. Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in
acute myocardial infarction complicated by cardiogenic SHOCK.
SHOCK investigators. Should we emergently revascularize occluded
coronaries for cardiogenic shock. N Engl J Med. 1999;341:625-634.
29. Chan V, Messika-Zeitoun D, Labinaz M, et al. Percutaneous mitral
repair as salvage therapy in patients with mitral regurgitation and
refractory cardiogenic shock. Circ Cardiovasc Interv. 2019;12:e008435.
30. Cheng R, Dawkins S, Hamilton MA, et al. Percutaneous mitral repair
for patients in cardiogenic shock requiring inotropes and temporary
mechanical circulatory support. JACC Cardiovasc Interv. 2019;12:
2440-2441.
31. Garcia S, Alsidawi S, Bae R, et al. Percutaneous mitral valve repair
with MitraClip in inoperable patients with severe mitral regurgitation
complicated by cardiogenic shock. J Invasive Cardiol. 2020;32:
228-231.
32. Siegel RJ, Biner S, Rafique AM, et al. The acute hemodynamic effects
of MitraClip therapy. J Am Coll Cardiol. 2011;57:1658-1665.
33. van Boven WJ, Gerritsen WB, Driessen AH, et al. Myocardial oxidative
stress, and cell injury comparing three different techniques for coronary
artery bypass grafting. Eur J Cardiothorac Surg. 2008;34:969-975.

SUPPORTING INF ORMATION
Additional supporting information may be found online in the
Supporting Information section at the end of this article.

How to cite this article: Estévez-Loureiro R, Shuvy M,
Taramasso M, et al. Use of MitraClip for mitral valve repair in
patients with acute mitral regurgitation following acute
myocardial infarction: Effect of cardiogenic shock on
outcomes (IREMMI Registry). Catheter Cardiovasc Interv. 2021;
1–9. https://doi.org/10.1002/ccd.29552

